NCNA NuCana plc Sponsored ADR

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
EN
13/10/2020

Underlying

NCNANuCana plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NuCana plc Sponsored ADR

 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Appoints Theresa Bruce as Chief Operating Officer EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. “We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana’s executive leadership team,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “Theresa brings more than...

January 6, 2026 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Presents Latest Data Demonstrating Clinical Activity and Favora...

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings EDINBURGH, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented the latest clinical data at the annual European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resi...

December 10, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Reports Third Quarter 2025 Financial Results and Provides Busin...

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development...

November 13, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738.   This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 ...

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of N...

October 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch